Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 15, 2022

SELL
$35.61 - $76.23 $7.66 Million - $16.4 Million
-215,109 Closed
0 $0
Q1 2022

May 09, 2022

SELL
$57.56 - $82.54 $2.38 Million - $3.41 Million
-41,331 Reduced 16.12%
215,109 $15 Million
Q4 2021

Feb 14, 2022

BUY
$72.5 - $100.68 $5.56 Million - $7.72 Million
76,634 Added 42.62%
256,440 $20 Million
Q3 2021

Nov 15, 2021

BUY
$90.24 - $124.05 $6.65 Million - $9.14 Million
73,651 Added 69.38%
179,806 $17.2 Million
Q1 2021

May 17, 2021

SELL
$116.57 - $155.01 $391,208 - $520,213
-3,356 Reduced 3.06%
106,155 $14 Million
Q4 2020

Feb 16, 2021

SELL
$99.61 - $142.12 $4.38 Million - $6.25 Million
-43,980 Reduced 28.65%
109,511 $14.5 Million
Q3 2020

Nov 13, 2020

BUY
$72.92 - $102.01 $2.92 Million - $4.09 Million
40,090 Added 35.35%
153,491 $15.6 Million
Q2 2020

Aug 14, 2020

BUY
$55.75 - $92.75 $1.44 Million - $2.39 Million
25,773 Added 29.41%
113,401 $9.86 Million
Q1 2020

May 15, 2020

BUY
$37.9 - $104.44 $1.65 Million - $4.55 Million
43,594 Added 99.0%
87,628 $5.08 Million
Q4 2019

Feb 14, 2020

BUY
$77.66 - $99.74 $1.4 Million - $1.79 Million
17,979 Added 69.0%
44,034 $4.07 Million
Q1 2019

May 09, 2019

SELL
$61.98 - $96.5 $803,074 - $1.25 Million
-12,957 Reduced 33.21%
26,055 $2.26 Million
Q4 2018

Feb 14, 2019

SELL
$56.04 - $82.66 $963,103 - $1.42 Million
-17,186 Reduced 30.58%
39,012 $2.46 Million
Q3 2018

Nov 14, 2018

BUY
$48.29 - $80.6 $1.44 Million - $2.41 Million
29,841 Added 113.22%
56,198 $4.44 Million
Q2 2018

Aug 14, 2018

BUY
$37.84 - $69.96 $997,348 - $1.84 Million
26,357 New
26,357 $1.58 Million

Others Institutions Holding EXAS

About EXACT SCIENCES CORP


  • Ticker EXAS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 176,960,000
  • Market Cap $10.3B
  • Description
  • Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for...
More about EXAS
Track This Portfolio

Track River Park Advisors, LLC Portfolio

Follow River Park Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of River Park Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on River Park Advisors, LLC with notifications on news.